Trial Profile
Effects of pioglitazone on insulin sensitivity and function of pancreatic α and β cells in type 2 diabetic patients with different body weight
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Apr 2018
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 01 Apr 2018 Results assessing effects of pioglitazone (PIO) on insulin resistance and first phase insulin secretion among obese and lean Chinese people with type 2 diabetes mellitus, were published in the Diabetes Therapy.
- 13 Jun 2017 Results assessing insulin sensitivity and pancreatic cell function presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 07 Jun 2017 New trial record